Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Boehringer Ingelheim
Baxter
Moodys
McKesson

Last Updated: November 29, 2021

DrugPatentWatch Database Preview

Claims for Patent: 8,592,644

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,592,644
Title:Transgenic animal for production of antibodies having minimal CDRS
Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.
Inventor(s): Harriman; William Don (Alameda, CA), Etches; Robert (San Mateo, CA), Leighton; Phil (San Francisco, CA)
Assignee: Crystal Bioscience Inc. (Emeryville, CA)
Application Number:12/854,722
Patent Claims:1. A transgenic chicken comprising a genome comprising a recombinant immunoglobulin light chain (IgL) locus comprising: a) a functional IgL gene comprising a nucleic acid encoding a light chain variable region comprising: i) a light chain CDR1, CDR2 and CDR3 regions; and ii) a light chain framework; and b) a plurality of pseudogenes that encode light chain variable regions each comprising: i) a light chain CDR1, CDR2 and CDR3 regions; and ii) a light chain framework region that is identical in amino acid sequence to the light chain framework of a) (ii); wherein said recombinant IgL locus comprises: in operable linkage: an intron region, a constant domain region-encoding region and a 3' untranslated region; wherein at least part of said intron region is endogenous to the genome of said transgenic chicken; and said nucleic acid of a) and pseudogene of b), are exogenous to the genome of said transgenic chicken, wherein each amino acid residue of the CDRs encoded by the pseudogenes of b) and each amino acid residue of the CDRs of the light chain variable region of a) are selected from the same group of 2 to 5 amino acid residues, wherein said plurality of pseudogenes are operably linked to said functional IgL gene and donate nucleotide sequences to the nucleic acid of a) by gene conversion in said transgenic chicken; and wherein said transgenic chicken expresses a recombinant immunoglobulin comprising a diversified form of said functional IgL variable region.

2. The transgenic chicken of claim 1, further comprising a recombinant immunoglobulin heavy (IgH) locus comprising: d) a functional IgH gene comprising a nucleic acid encoding a heavy chain variable region comprising: i) a heavy chain CDR1, CDR2 and CDR3 regions; and ii) a heavy chain framework; and d) a plurality of pseudogenes that encode heavy chain variable regions each comprising: i) a heavy chain CDR1, CDR2 and CDR3 regions; and ii) a heavy chain framework region that is identical in amino acid sequence to the heavy chain framework of a) (ii); wherein each amino acid residue of the CDRs encoded by the pseudogenes of e) and each amino acid residue of the CDRs of the heavy chain variable region of d) are selected from the same group of 2 to 5 amino acid residues, wherein said recombinant IgH locus comprises: in operable linkage: an intron region, a constant domain region-encoding region and a 3' untranslated region; wherein said intron region is endogenous to the genome of said transgenic chicken; and said nucleic acid of c) and pseudogene of d), are exogenous to the genome of said transgenic chicken, wherein said plurality of pseudogenes are operably linked to said functional IgH gene and donate nucleotide sequences to the nucleic acid of d) by gene conversion in said transgenic chicken and wherein said transgenic chicken expresses a recombinant immunoglobulin comprising a diversified form of said functional IgH variable region.

3. The transgenic chicken of claim 1, wherein: at least one of the 2 to 5 amino acids in said group is a tyrosine or tryptophan residue, and at least one of the 2 to 5 amino acids in said group is an alanine, glycine or serine residue.

4. The transgenic chicken of claim 1, wherein said light chain framework is a human framework.

5. The transgenic chicken of claim 4, wherein said light chain framework is identical in amino acid sequence to a human germline framework.

6. The transgenic chicken of claim 1, wherein said immunoglobulin light chain locus comprises: in operable linkage: an intron region, a constant domain-encoding region and a 3' untranslated region; wherein said intron region, said constant domain-encoding region and said 3' untranslated region are endogenous to the genome of said transgenic chicken; and, said nucleic acid of a) and pseudogenes of b), wherein said nucleic acid of a) and pseudogenes of b) are exogenous to the genome of said transgenic chicken.

7. The transgenic chicken of claim 1, wherein said immunoglobulin light chain locus comprises at least 10 of said pseudogenes.

8. The transgenic chicken of claim 1, wherein at least one of said plurality of pseudogenes of b) is in reverse orientation relative to the nucleic acid of a).

Details for Patent 8,592,644

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 1986-06-04 ⤷  Try it Free 2029-08-13
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try it Free 2029-08-13
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Mallinckrodt
Baxter
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.